Annie Joseph @anniejoseph - Bluesky Profile

Listening, learning and leading: empowering the next generation through podcast reviewing Launched in spring 2024, the podcast Communicable, hosted by the editors of CMI Communications, has quickly become a trusted forum for exploring emerging and sometimes controversial issues in infectio...

📣Extra proud of this one:

ESCMID's Trainee Assoc @taescmid.bsky.social reflects on its critical role in peer-reviewing #Communicable podcast episodes:

Our model "sets a precedent for inclusive academic publishing" 😀🎙️
#IDSky #clinmicro #MedEd #MedSky #peerreview

www.cmi-comms.org/article/S295...

02.12.2025 16:14 — 👍 3 🔁 3 💬 0 📌 0

Twitter remains a haven of harassment To the Editor,I read with interest the article by Stone and Schwartz “Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter),” October 2025 [1]. For disclosure, I was an early ScienceTwitter adopter, having established my account in 2009. Before Elon Musk purchased the site in October 2022, I had approximately 132 000 followers and received my “blue check” verification in 2016. I coauthored a 2020 publication touting the “viral power of Twitter for infectious disease” [2]. I coedited a book on the West African Ebola epidemic with colleagues I met via Twitter and credit the site with other collaborations and talk invitations over the years. All of this is to say that I have seen the highs and lows of the site in my 16 years’ worth of observations.One thing I find missing in the Stone and Schwartz [1] analysis is a discussion of the social cost of harassment and threats on Twitter/X, particularly for women. To be sure, Twitter was never a bucolic haven of civility. A preMusk, 2018 report by Amnesty International detailed a “shocking scale of online abuse against women” on the site [3], which increased further during the height of the COVID-19 pandemic [4]. I have personally received harassment from my years on Twitter, ranging from threats to my livelihood, to sexual assault, to wishes of death, and other graphic physical abuse. Most women scientists I know have received similar threats to one extent or another, and it is generally worse for women colleagues of colour [3]. Outspoken women with deep scientific expertise are intensely threatening to patriarchal norms and the extremists who have made their home on Musk’s Twitter.Stone notes that “Staying the course needs a thick skin—but ultimately science and reason can still shine even in the most hostile environment.” I would have once agreed with that statement, but I am no longer convinced. As noted in the original article, part of Musk’s changes upon site purchase were to eliminate much of the existing trust and safety team; to loosen moderation and allow for, or even reward via algorithmic boosting, misinformation on the platform; and to bring back users who had been banned under the prior owners, including those who had promoted vitriolic campaigns against scientists. The already-toxic platform showed an increase in hate speech as an unsurprising outcome [5]. Although the reporting feature was always unreliable, now the option to report an individual user or tweet has been removed altogether, an acknowledgement that there is no behaviour too odious to result in removal from the platform.I have been a science communicator on various sites since 2002, from internet fora to science blogs to Twitter and other social media sites. The depth of my skin is not the issue. Since the Musk takeover, 20 000 of my followers left the site. Because I will not participate in Musk’s new version of pay-to-play verification to boost the position of my tweets in the algorithm, my engagement on the site cratered. Although my profile still exists, I ended active participation in the summer of 2024. I no longer recommend the site to trainees and junior colleagues, as the risk of personal hazard is too great for the minimal engagement in return. Although neither is without fault, I currently find more engagement and productive discussion at Bluesky and Facebook.CRediT authorship contribution statementTara C. Smith: Conceptualization, Writing – original draft.Declaration of competing interestTara Smith has no COI to disclose. No funding was provided for this manuscript. No AI was used in its writing.

Author with 132K followers lost 20K post-Musk takeover 😞. Harassment, esp. vs women, rose 📈. Reporting removed, engagement crashed. Recommends Bluesky & Facebook over X.

#idsky

02.12.2025 14:30 — 👍 2 🔁 1 💬 0 📌 0

Diagnostic stewardship improves pt care, saves money, & makes doctors' lives easier... what's not to love?

Recording this ep gave me loads of ideas to put into practice...

01.12.2025 08:59 — 👍 4 🔁 2 💬 0 📌 0

<em>Communicable</em> episode 26: SNAP out of it—rethinking antistaphylococcal penicillins for <em>Staphylococcus aureus</em> bacteraemia, the SNAP trial PSSA/MSSA results In this first-ever collaboration between Communicable and Breakpoints, the podcast of the US Society of Infectious Diseases Pharmacists, hosts Angela Huttner (Geneva, Switzerland) and Erin McCreary (Pittsburgh, USA) join trial investigators Josh Davis (Newcastle, Australia) and Steven Tong (Melbourne, Australia) to unpack the first results coming from the SNAP adaptive platform trial, which were recently presented at ESCMID Global in Vienna. Learn whether penicillin and cefazolin are non-inferior to—and maybe even safer than—flucloxacillin for penicillin-susceptible and methicillin-susceptible Staphylococcus aureus, respectively.This episode was edited by Julie Anne Justo, transcribed by Katie Lambert and Sarah Groome, and peer-reviewed by Megan Klatt and Lacy Worden. Communicable and Breakpoints released this episode on 5 May 2025.Declaration of competing interestS.Y.C.T. has served on an advisory board for AstraZeneca for a staphylococcal monoclonal antibody programme and receives royalties from UpToDate for editing S. aureus–related content. E.K.M. has previously served on scientific advisory boards for the following pharmaceutical companies: Abbvie, Basilea, Melinta, GSK, and serves on the DSMC for the SNAP trial. Other authors declare no financial interests/personal relationships that may be considered as potential competing interests. Note on conflict of interest for SNAP Data Safety Monitoring Committee (DSMC) members:Conflicts of interest were evaluated when choosing individuals to serve on the SNAP DSMC. Aside from being compensated for their duties on the committee, DSMC members have no ongoing financial relationships that relate to the trial and are not involved in the conduct of the trial in any role other than that of a DSMC member. DSMC members have no intellectual conflict of interest or bias and reviewed SNAP data in a fully objective manner.Related podcast episodeCommunicable Episode 26: SNAP out of it - the SNAP trial PSSA/MSSA results https://share.transistor.fm/s/2a3c3bb4Further reading[1]Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG Jr. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–61. DOI:https://doi.org/10.1128/CMR.00134-14.[2]SNAP Adaptive trial platform/results of the PSSA & MSSA domains:• https://www.snaptrial.com.au/ESCMID Global April 2025 presentation:• www.online.escmid.org *• https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/[3]CloCeBa trial results (ESCMID Global April 2025 presentation):• www.online.escmid.org *• https://www.escmid.org/congress-events/escmid-global/programme/scientific-programme/[4]CAMERA 2 trial; Tong SY, Lye DC, Yahav D, et al. Without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA. 2020;323(6):527–37. DOI:https://doi.org/10.1001/jama.2020.0103.[5]POET trial; Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–24. DOI:https://doi.org/10.1056/NEJMoa1808312.[6]POET trial follow-up: Pries-Heje MM, Wiingaard C, Ihlemann N. Five-year outcomes of the partial oral treatment of endocarditis (POET) trial. N Engl J Med. 2022;386:601–02. DOI:https://doi.org/10.1056/NEJMc2114046.*Note on access to online video of ESCMID Global presentations:•In the six months following the congress:• Non-ESCMID members have access if they registered for ESCMID Global• Members have access only if they registered for ESCMID Global•Six months after the congress:• Non-members do not have access, whatever their ESCMID Global registration status• All members have access, whatever their ESCMID Global registration status

Podcast reveals SNAP trial: penicillin & cefazolin non-inferior & possibly safer than flucloxacillin for PSSA/MSSA. Episode aired May 5, 2025. 🎧🦠 #InfectDis

#idsky

30.11.2025 13:00 — 👍 4 🔁 1 💬 0 📌 0

📣 New #Communicable drops Mon 1 Dec!
Annie Joseph & Angela Huttner host Dan Morgan (USA) & Valerie Vaughn (USA) to discuss diagnostic stewardship - what it means and why we should do it.

#IDSky #clinmicro #MedSky #meded

27.11.2025 10:40 — 👍 10 🔁 5 💬 0 📌 0

Communicable E40: AMR in conflict and crisis zones It’s World AMR Awareness Week (WAAW) and we have prepared a special...

🎙️ Just published: Communicable E40: AMR in conflict and crisis zones

Hosted by Nav Narayanan & Thomas Tängdén

w/ invited guests Aula Abbara (UK), Guido Granata (Italy), Tuomas Aro (Finland)

Listen on #Communicable:

#IDSky #Clinmicro #WAAW2025 #AMR @taescmid.bsky.social

16.11.2025 23:00 — 👍 6 🔁 6 💬 2 📌 2

This study by Paul Little's group really could impact AMS in the community, the design and execution is so impressive 👏🏼 👏🏼 👏🏼

Already put into action for my own 🤧 this season!

#IDsky
#AMSsky
#clinmicro

14.11.2025 07:24 — 👍 3 🔁 0 💬 0 📌 0

Treatment of ENterococcus Trial (TENT) clinical attitudes and equipoise survey Take this survey powered by surveymonkey.com. Create your own surveys for free.

UK Infection & related specialty clinicians - we would like your views on the design of RCTs to optimise treatment of Enterococcal bacteraemia.

Relevant for ID, microbiology, cardiologists etc.

10.11.2025 12:55 — 👍 2 🔁 1 💬 0 📌 2

🤣 🤣

05.11.2025 22:28 — 👍 2 🔁 0 💬 0 📌 0

Who knows, you guys might even get temocillin soon too! 😉

My take: IV fosfo has a couple of handy off-label uses... tricky VRE infections (in combo), occasional meningitis with unusual orgs/allergies, resistant pyelo when beta-lactams truly contraindicated.

Sodium load is a real issue tho.

05.11.2025 20:46 — 👍 4 🔁 1 💬 2 📌 0

🦟 Dengue 🦟 is on the rise!

I learnt so much from our experts on this new ep of Communicable brought to you by @cmicomms.bsky.social 💙

03.11.2025 06:55 — 👍 2 🔁 0 💬 0 📌 0

📣 New #Communicable drops Mon 3 Nov!
@anniejoseph.bsky.social & Nav host @andre-siqueira.bsky.social (Brazil) & Steven Lim (Malaysia) to discuss #dengue as a rising global health burden, how to diagnose & manage it, and what's in the therapeutic pipeline 🔍

@dndi.org #denguealliance #IDSky

30.10.2025 10:30 — 👍 8 🔁 4 💬 0 📌 0

📣In a longitudinal analysis of top ID journals, gender balance is projected for women first authors in 2028 - but for women last authors, only in 2043
The proportion of women editors is projected to remain low

https://www.cmi-comms.org/article/S2950-5909(25)00084-8/

Katharina #IDSky #womeninstem

27.10.2025 09:56 — 👍 6 🔁 6 💬 0 📌 0

Great leadership from both societies on this! 👏🏼 👏🏼

A nice push for adoption in NHS units that are not doing it yet.

#IDsky

22.10.2025 10:03 — 👍 10 🔁 1 💬 0 📌 0

Complicated vs uncomplicated should be a definition that can be decided by the first clinician seeing the pt...makes so much sense 👌

IV cefuroxime tid-qid for urosepsis is 1st line in many UK hospitals due to low resistance, to avoid 3GCs & C.diff risk 💩

And the quinolone debate goes on!! #IDsky

20.10.2025 16:43 — 👍 4 🔁 0 💬 0 📌 0

Communicable E38: Why do you have to be so complicated? The 2025 IDSA Complicated UTI Guidelines In this episode of Communicable, Erin McCreary and Angela Huttner are...

🎙️ Just published: Communicable E38: Why do you have to be so complicated? The 2025...

Hosted by @angelahuttner.bsky.social & @erinmccreary.bsky.social

w/ invited guests: Barbara Trautner @bwtrautner.bsky.social & Valéry Lavergne

Listen on Communicable:

#IDSky #Clinmicro #MedSky #UTIsky

19.10.2025 22:01 — 👍 8 🔁 4 💬 1 📌 1

Somehow forgot to share this post this week.

Was fun event, well attended (70+ people!), honour to be asked to present, and expertly chaired by @anniejoseph.bsky.social

Onto the next one! 👏
#IDSky #UTISky @escmid.bsky.social

19.10.2025 10:54 — 👍 2 🔁 1 💬 0 📌 0

That A3 domain of piptaz + macrolide that makes me die a little inside. The pk of piptaz in lungs is all over the place, and no need for broad GNB cover in CAP 😢

19.10.2025 08:44 — 👍 2 🔁 0 💬 0 📌 0

Agree @drrossanarosa.bsky.social I found that debate fairly compelling, though I'm not sure I realised how heavy on the Staph aureus the causative organism was, not what we see in UK (pneumo predominant).

19.10.2025 08:33 — 👍 1 🔁 0 💬 1 📌 0

Ermmm 😬

19.10.2025 08:25 — 👍 3 🔁 0 💬 1 📌 0

🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...

19.10.2025 04:34 — 👍 38 🔁 16 💬 0 📌 5

📣 New #Communicable drops Mon 20 Oct!
@angelahuttner.bsky.social & @erinmccreary.bsky.social welcome Barbara Trautner @bwtrautner.bsky.social & Valéry Lavergne, the co-chairs of the first IDSA guidelines for complicated UTIs, to discuss this important milestone!

#IDSky #UTIsky #MedSky #clinmicro

16.10.2025 12:17 — 👍 14 🔁 3 💬 0 📌 1

Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter) Social media is a cultural and communications phenomenon that is an integral part of life in the 2020s. Twitter was founded in 2006 and became a leading social media platform with an active user base ...

New pro/con perspective piece by @drneilstone.bsky.social & yours truly

Joining the X-odus: Contrasting perspectives on whether infection specialists should leave X (formerly Twitter)

That I'm sharing it here belies where I stand on the issue

www.cmi-comms.org/article/S295... #IDSky

16.10.2025 01:47 — 👍 67 🔁 15 💬 8 📌 5

Logo for the ADVANCE-ID group's 'Bacterial and fungal infections newsletter'.

David Paterson and the ADVANCE-ID team are doing a lot of work for us summarizing recent literature on bacterial & fungal infections & therapies. If you aren't already receiving their bimonthly newsletters, you should! ad-id.co/subscribe

#IDSky #Clinmicro

15.10.2025 04:42 — 👍 8 🔁 6 💬 1 📌 0

Banner announcing the journal's new series on "the person behind the name" and a call for articles

✨NEW open call for articles 📣
What's in a name? That's exactly what we want you to tell us in this new series we have just launched, "Person behind the name". Read the call and submit your piece here: www.cmi-comms.org/article/S295...

#IDSky #clinmicro

09.10.2025 07:38 — 👍 4 🔁 3 💬 0 📌 1

🆕🔥Streptococcal endocarditis: a meta-analysis of species dependant risk by 🌟s @drtoddlee.bsky.social
🌟Updated figure 🌟Infective endocarditis prevalence of streptococcal species vs. proportion of streptococcal species bacteraemia #idsky #EMIMCC
www.sciencedirect.com/science/arti...

25.08.2025 16:18 — 👍 28 🔁 11 💬 1 📌 1

I loved the history too! And the potential future!
Glad you listened & liked 💙
@mbaldwin.bsky.social & Serge Horbach had great perspectives.

08.10.2025 20:13 — 👍 2 🔁 0 💬 0 📌 0

The person behind the name – an open call for articles in a new series for CMI Communications

What’s in a name?” Even microbes carry stories. @cmicomms.bsky.social
is launching a new series exploring the people behind eponymous organisms—those whose names live on through microbes like Escherichia or Pasteurella. Open call for submissions #idsky
www.sciencedirect.com/science/arti...

08.10.2025 17:01 — 👍 9 🔁 5 💬 0 📌 0

a cartoon penguin reading a newspaper with the words good news written above it ALT: a cartoon penguin reading a newspaper with the words good news written above it

ESGUTIs Newsletter “The Fall Edition” is out! Check it out: www.escmid.org/esguti/

AND… GRAND ROUNDS next Tuesday! Register now, it will be super exciting.

06.10.2025 18:17 — 👍 2 🔁 1 💬 1 📌 0

Glad you enjoyed it! 😊

06.10.2025 17:30 — 👍 1 🔁 0 💬 0 📌 0

Annie Joseph

Latest posts by anniejoseph.bsky.social on Bluesky

@anniejoseph is following 20 prominent accounts